Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Galectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Galectin Therapeutics Inc. Common Stock (GALT) stock saw a decline, ending the day at $1.04 which represents a decrease of $-0.96 or -48.00% from the prior close of $2. The stock opened at $1.18 and ...

Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. The stock lost more than half its value, falling to about 91 cents ...

After hours: December 24 at 4:56:43 PM EST The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this ...

Galectin Therapeutics (GALT) reported results from NAVIGATE clinical trial evaluating belapectin in patients with Metabolic ...

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 85.37% +13.41, ...

(RTTNews) - Galectin Therapeutics (GALT) reported results from NAVIGATE clinical trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal ...